Orna Therapeutics, a leading biotechnology company developing a proprietary pipeline of in vivo therapies across a broad range of autoimmune and oncology indications, today announced an upcoming ...
RPM, a leading non-asset-based logistics provider specializing in finished vehicle and freight transportation, is pleased to ...
(per RECIST v1.1) at the 100 mg APR-1051 dose level in heavily pretreated gastrointestinal and gynecologic malignancies Disease stabilization observed in patients with tumors harboring mutations ...
Spyre Therapeutics, Inc. (NASDAQ: SYRE), a clinical-stage biotechnology company pioneering long-acting antibodies and antibody combinations to redefine the standard of care for inflammatory bowel ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback